ICHIRO ABE. Efficacy and Safety of Low-Dose Ipragliflozin, a Selective Sodium Glucose Transporter 2 Inhibitor, in Patients with Type 2 Diabetes Mellitus. International Journal of Allied Medical Sciences and Clinical Research, [S. l.], v. 4, n. 3, p. 376–382, 2020. DOI: 10.61096/ijamscr.v4.iss3.2016.376-382. Disponível em: https://ijamscr.com/ijamscr/article/view/283. Acesso em: 16 apr. 2026.